The complex relationship between genotype, pathology and phenotype in familial dementia
Affiliations
- PMID: 32927063
- DOI: 10.1016/j.nbd.2020.105082
Abstract
Causative genes involved in familial forms of dementias, including Alzheimer's disease (AD), frontotemporal lobar degeneration (FTLD) and dementia with Lewy bodies (DLB), as well as amyotrophic lateral sclerosis and prion diseases where dementia is present as a significant clinical feature, are associated with distinct proteinopathies. This review summarizes the relationship between known genetic determinants of these dementia syndromes and variations in key neuropathological proteins in terms of three types of heterogeneity: (i) Locus Heterogeneity, whereby mutations in different genes cause a similar proteinopathy, as exemplified by mutations in APP, PSEN1 and PSEN2 leading to AD neuropathology; (ii) Allelic Heterogeneity, whereby different mutations in the same gene lead to different proteinopathies or neuropathological severity, as exemplified by different mutations in MAPT and PRNP giving rise to protein species that differ in their biochemistry and affected cell types; and (iii) Phenotypic Heterogeneity, where identical gene mutations lead to different proteinopathies, as exemplified by LRRK2 p.G2019S being associated with variable Lewy body presence and alternative AD neuropathology or FTLD-tau. Of note, the perceived homogeneity in histologic phenotypes may arise from laboratory-specific assessment protocols which can differ in the panel of proteins screened. Finally, the understanding of the complex relationship between genotype and phenotype in dementia families is highly relevant in terms of therapeutic strategies which range from targeting specific genes, to a broader strategy of targeting a downstream, common biochemical problem that leads to the histopathology.
Keywords: Allelic heterogeneity; Alzheimer's disease; Frontotemporal lobar degeneration; Gene locus heterogeneity; Lewy body diseases; Phenotypic heterogeneity; Prion diseases.
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of Competing Interest The authors have no Conflict of Interest to declare.
Similar articles
- Neuropathologic diagnostic and nosologic criteria for frontotemporal lobar degeneration: consensus of the Consortium for Frontotemporal Lobar Degeneration.Acta Neuropathol. 2007 Jul;114(1):5-22. doi: 10.1007/s00401-007-0237-2. Epub 2007 Jun 20.PMID: 17579875 Free PMC article.
- Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration.J Neurol Sci. 2008 Jul 15;270(1-2):94-8. doi: 10.1016/j.jns.2008.02.010. Epub 2008 Mar 19.PMID: 18353371
- Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype.Brain Pathol. 2017 Nov;27(6):723-736. doi: 10.1111/bpa.12486. Epub 2017 Mar 2.PMID: 28100023 Review.
- Glial fibrillar acidic protein in the cerebrospinal fluid of Alzheimer's disease, dementia with Lewy bodies, and frontotemporal lobar degeneration.J Neurochem. 2016 Jan;136(2):258-61. doi: 10.1111/jnc.13399. Epub 2015 Nov 11.PMID: 26485083
- TDP-43 proteinopathies: pathological identification of brain regions differentiating clinical phenotypes.Brain. 2015 Oct;138(Pt 10):3110-22. doi: 10.1093/brain/awv220. Epub 2015 Jul 31.PMID: 26231953
No hay comentarios:
Publicar un comentario